drugset / Trial / NCT04810494

Intranasal Lidocaine for Prevention of Postoperative Nausea and Vomiting.

NCT04810494 ↗

RandomizedSingle-groupQuadruple-blindPrevention

Summary

Postoperative nausea and vomiting (PONV) are common and continue to be persistent problems following general anesthesia. Intranasal lidocaine has been used for the treatment of migraine. The theoretical basis for this effect of intranasal lidocaine on migraine relief is reported to be due to its action on the sodium receptors within the sphenopalatine ganglion. Although there is no reported association between PONV and migraines, injecting lidocaine within the sphenopalatine ganglion has proven to be effective in reducing PONV in endoscopic sinus surgery. The purpose of this study is to investigate the efficacy of intranasal 2% lidocaine in preventing PONV.

Timeline

Start
2022-10-01
Primary completion
2023-03-31
Completion
2023-06-30

Outcome

Outcome not reported

Stopped: “Change in study team”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified 0.5 ml Intranasal
Subject Lidocaine Other / unclassified 2 % Intranasal

Indications

No indication recorded.